Adamas Pharmaceuticals develops innovative treatments for chronic neurologic disorders. 

Biotechnology

Pharmaceutical

Therapeutics

Adamas Pharmaceuticals

Ms. Mathieson joined Adamas as Head of Corporate Communications and Engagement in February 2019. She previously served as Chief Executive Officer for Research Autism, a non-profit organization focused on research and information provision in the UK. Prior to this she held various global leadership roles at GlaxoSmithKline plc. including Global Head of Internal Engagement overseeing strategy, brand, leadership, and engagement for GSK Consumer Healthcare; Global Head of Pipeline (R&D) communications with a focus on financial, scientific and crisis communications, and new product approvals; and Director, Corporate Product Communications. During her time at Pfizer Inc., Ms. Mathieson served as Head of Product Communications for Pfizer UK Ltd, responsible for over 20 products at all stages of product development and spent the early years of her career in medical education and communications agencies, leading corporate communications, public relations, advocacy and medical education across a wide range of disease areas. She has a Bachelor’s of Science degree in BioMedical Sciences.

Sarah Mathieson

Mr. Mahoney is a private equity investor and currently serves on the board of directors of Symantec Corporation, [Corcept Therapeutics](/org/corcept-therapeutics), and [Mercy Corps](/org/mercy-corps), and as a Trustee of the Schwab Mutual Funds and [SFMOMA](/org/san-francisco-museum-of-modern-art). Previously, Mr. Mahoney acted as co-chief executive officer of [McKesson](/org/mckesson) HBOC, Inc. (now [McKesson](/org/mckesson) Corporation) and as chief executive officer of [McKesson](/org/mckesson) LLC from July 1999 to February 2001. He joined [McKesson](/org/mckesson) in 1990 as Vice President for Strategic Planning and managed the company’s relationships with the pharmaceutical industry. Prior to joining [McKesson](/org/mckesson), Mr. Mahoney was a principal with [McKinsey & Company](/org/mckinsey-company) from 1981 to 1990. Mr. Mahoney is an honors graduate from [Harvard Business School](/org/harvard-business-school) and [Princeton University](/org/princeton).

David L. Mahoney

Dr. Went is the Founder of [Adamas Pharmaceuticals](/org/adamas-pharmaceuticals) and guided the company’s growth as CEO and Chairman from inception to September 2019, when he became a strategic advisor to the company. Dr. Went developed the original technology platform, based upon the understanding and modelling of time-dependent biological phenomena. He has steered Adamas through the licensing of assets related to Namenda XR and Namzaric to Forest Laboratories (now [Allergan](/org/allergan)), the company’s IPO, and now commercial preparation for the potential launch of a new medicine for patients with Parkinson’s disease. Prior to Adamas, Dr. Went co-founded CuraGen Corporation in 1992, one of the first genomics companies, where he served as Executive Vice President and Director. Dr. Went has served on the board of directors of Angelica, Parallele Biosciences and Tethys Biosciences.

Dr. Went has published in the fields of catalysis, spectroscopy, DNA sequencing, gene expression profiling, neuroscience, influenza and neurology. Dr. Went is an inventor on over 70 issued and pending patents. He received his Ph.D. in Chemical Engineering from the University of California, Berkeley, his B.S. in Chemical Engineering from [Carnegie Mellon University](/org/carnegie-mellon-university), and did additional post-doctoral work at [Cornell University](/org/cornell-university).

Gregory T. Went

Anna Richo, J.D., is General Counsel, Chief Compliance Officer, and Corporate Secretary at Cargill, Inc. Ms. Richo brings over 30 years of leadership experience managing legal and compliance functions within the biotechnology and pharmaceutical industry, including UCB, [Amgen](/org/amgen) and Baxter Healthcare as well as prior public-company Board, Audit and Finance Committee experience at Cytyc Corporation. Ms. Richo’s successful career path includes leadership roles in biotechnology and pharmaceutical companies as general counsel and leading compliance, intellectual property and corporate litigation. Ms. Richo has previously been recognized as one of the ’Top 15 Women in Pharma’. She holds a bachelor’s degree in industrial and labor relations from [Cornell University](/org/cornell-university) and a J.D. degree from [DePaul University](/org/depaul-university) College of Law. She is a member of the Board of Trustees for [DePaul University](/org/depaul-university).



Anna Richo

Mr. Prentiss joined the company in April 2015 as VP, Finance and Controller before becoming the Chief Accounting Officer of Adamas in September 2017. Before coming to Adamas, he was most recently VP, Finance and Controller at InterMune, Inc., a biotechnology company, until its acquisition by Roche. Prior to that, Mr. Prentiss was the Controller at Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company and held the same position at [MannKind](/org/mannkind) Corporation, a biotechnology company, as well as a variety of other finance roles. Prior to joining [MannKind](/org/mannkind), Mr. Prentiss was a Senior Manager at KPMG LLP in the assurance practice. Mr. Prentiss received a Bachelor’s of Science degree in Accounting from [Loyola Marymount University](/org/loyola-marymount-university), and a Masters of Business Administration from [Indiana University](/org/indiana-university). Mr. Prentiss is a CPA licensed in California.


Christopher B. Prentiss

Eric joined as Head of Human Resources at Adamas in November 2019 with over 20 years of experience leading and developing human resources and legal functions at high-growth private and public companies. Prior to joining Adamas, he was the Head of Human Resources for [Vir Biotechnology](/org/vir-biotechnology), helping the company grow from approximately 65 employees to 250 employees. Eric also led the human resources and facilities functions at Tessera Technologies, where he helped manage the company through a complete transformation of board, senior leadership, organizational focus, culture, and values. He has held various positions leading both legal and human resource functions at pharma, biotech, and technology companies in the Bay Area. Eric holds a JD from Washington University in St. Louis and an AB in Asian Studies from [Dartmouth College](/org/dartmouth).

Eric Schlezinger

Mr. McFarlane joined Adamas as Chief Executive Officer and member of the Board of Directors in September 2019. He brings over two decades of global biopharmaceutical and life sciences experience delivering value to patients suffering from serious illnesses. Mr. McFarlane has delivered growth in both specialty and orphan products in the United States, Europe, Asia and Latin America. He most recently served as Chief Operating Officer of Retrophin, Inc. with principal responsibility for global commercial operations, corporate development, patient services, and program and alliance management. Previously he held executive and general management positions at leading biopharmaceutical companies, including UCB, Genzyme, and Sangstat Medical Corporation. Mr. McFarlane served as an officer and enlisted soldier in the United States Army Reserves. He holds a B.S. and M.S. in Nursing from the [University of Florida](/org/university-of-florida).

Neil F. McFarlane

Jill Jene joined Adamas in August, 2020, as Vice President and Head of Corporate Development, Strategy, Portfolio Planning and Alliance Management. Jill brings more than 20 years of biopharmaceutical BD experience and a deal sheet close to $4 billion to her new role at Adamas. Before joining Adamas, Jill was Vice President of Business Development for PDL, a publicly traded biotechnology company. Jill was responsible for developing the strategy and executing deal-making to maximize value for shareholders. Before PDL, Jill led BD and strategy at twoXAR where she led deal-making, closing 6 new partnerships and securing Series A funding. Prior to twoXAR, Jill was at Depomed, where she led over 36 transactions including licensing and M&A deals including acquiring 4 commercial franchises. Earlier in her career, Jill held BD positions at Baxter International, the 3M Company (Pharmaceutical Division now part of Valeant) and Cell Genesys (acquired by Biosante). Jill holds an BS from Bradley, a MS and PhD in Chemistry from [Northwestern University](/org/northwestern-university), and an MBA from [DePaul University](/org/depaul-university).

Jill Jene

Vijay joined Adamas as Chief Commercial Officer in May 2019 from Amgen Inc. where he served in a variety of sales and marketing roles of increasing responsibility in multiple therapeutic areas. Most recently, Vijay was Executive Director and Integrated Commercial Lead for the Multiple Myeloma franchise with responsibility for national sales, brand marketing, and regional marketing teams. He brings extensive US product launch experience, successfully leading the market entry of new entities, expanded indications for approved products, as well as new drug-delivery systems. He has led strategy and execution for multiple brands, including Neulasta®, XGEVA®, Vectibix®, and Kyprolis®, with a demonstrated track record of generating robust demand growth in highly competitive markets. Vijay started his professional career as a scientist in the field of Immuno-Oncology, earning his PhD at the University of Texas, M.D. Anderson Cancer Center and gaining experience in both academic and pharmaceutical research settings. He also earned an MBA in Healthcare Management from the Wharton School at the [University of Pennsylvania](/org/university-of-pennsylvania).

Vijay Shreedhar

Adrian joined Adamas as Chief Medical Officer in September 2020. He has over 20 years of global drug development and pharmaceutical experience, both in academia and industry, with a keen focus on unmet medical needs in patients with serious disorders. Adrian joins Adamas from BioMarin, where he initially served as head of Medical Affairs EUMEA progressing to becoming the head of global Medical Affairs, a position he held for the last 4 years. During this time, Adrian oversaw the launch of 6 products. Prior to BioMarin, he held senior positions responsible for clinical development and as principal investigator for several products at the Phase 1 unit at Chiltern, and positions in pharmacovigilance, clinical development and medical affairs at Paraxel, Icon and Astellas. Before joining the industry, Adrian worked as clinical research fellow at UCLA Cedar Sinai and as resident cardiothoracic surgery at Erasmus University Medical Center. Adrian obtained his medical degree from Erasmus University Medical School, Rotterdam in the Netherlands, obtained his post graduate specialization in pharmaceutical medicine from the Faculty of Pharmaceutical Medicine in London UK, and is GMC board certified in pharmaceutical medicine in the UK.



Adamas Pharmaceuticals

Org chart

Teams

Leadership Team

Board of Directors

CEO and Executive Team

Founding Team

Discover similar companies